NCT05712161View on ClinicalTrials.gov

Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: Early Feasibility Study

NAActive, not recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 7, 2023

Primary Completion Date

December 29, 2023

Study Completion Date

December 31, 2033

Conditions
Aortic StenosisSymptomatic Aortic StenosisSevere Aortic Valve StenosisAortic Valve Calcification
Interventions
DEVICE

DurAVRTM THV System

The DurAVR™ Transcatheter Heart Valve (THV) is a balloon expandable transcatheter aortic valve

Trial Locations (5)

10032

Columbia University Medical Center/NYPH, New York

10467

Montefiore Medical Center, The Bronx

44195

Cleveland Clinic Foundation, Cleveland

48109

University of Michigan, Ann Arbor

85712

Tucson Medical Center, Tucson

Sponsors
All Listed Sponsors
lead

Anteris Technologies Ltd.

INDUSTRY

NCT05712161 - Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: Early Feasibility Study | Biotech Hunter | Biotech Hunter